About me

Edwin completed his BSc (Hons) in Anatomy and Cell Biology at McGill University, and his PhD in Medical Science at the University of Toronto, followed by postdoctoral research posts at the University of Cambridge (with Professor Tony Green) and Harvard University (with Drs. Ann Mullally and Ben Ebert) where he investigated the molecular biology of a group of age-associated cancers called the chronic myeloproliferative neoplasms (MPN). He established his independent research group on a John Goldman Fellowship at the University of Leeds in 2015, and moved to the University of Westminster in January 2020.

Edwin's main research interest is to understand the molecular processes that govern how blood stem cells turn into leukaemia cells and how to translate these insights into the development of new cancer drugs. To date, his work has illuminated mechanisms whereby aberrant JAK/STAT pathways influence diverse aspects of cell function, including DNA replication and repair, lineage fate choice and immune activity. He has 20 years of research experience in blood cancer research, has published >25 papers in peer-reviewed journals such as Cancer Cell, PNAS, Cancer Discovery, Blood and Oncogene, and his group's work has been presented at several major international conferences, including the American Society of Haematology,  European Hematology Association and American Association for Cancer Research. 

For more information on research in the lab, please visit www.edwinchenlab.org.

Teaching

Edwin is a Lecturer in Molecular Biology, and he is involved with the following courses: Medical Genetics and Genomics, Biochemistry.

Research

Kargas V, Castro-Hartmann P, Escudero-Urquijo N, Dent K, Hilcenko C, Sailer C, Zisser G, Marques-Carvalho MJ, Pellegrino S, Wawiórka L, Freund SM, Wagstaff JL, Andreeva A, Faille A, Chen E, Stengel F, Bergler H, Warren AJ. (2019). Mechanism of completion of peptidyltransferase centre assembly in eukaryotes. eLife. 8:e44904

Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally A. (2018). Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 131:782-786

Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman J-A, Schneider RK, Al-Shahrour F, Mullally A. (2016). Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discovery. 6:368-381

Ahn JS, Li J, Chen E, Kent DG, Park HJ, Green AR. (2016). JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation. Oncogene. 35:2235-2246 

Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL. (2016). Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nature Medicine. 22:288-297 

Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron J-M, Dohner K, Vannucchi AM, Besses C, Green AR. (2016). STAT1 activation in association with JAK2 exon 12 mutations. Haematologica. 101:e15-e19 

Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullaly A. (2015). RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Reports. 13:2345-2352  

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NCP. (2015). Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.. Nature Communications. 6:6691 

Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A. (2015). Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 125:327-335 

Chen E, Mullally A. (2014). How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?. Hematology. 2014:268-276 

Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR. (2014). JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.. Proceedings of the National Academy of Sciences of the United States of America. 111:15190-15195 

Li J, Kent DG, Godfrey AL, Manning H, Nangalia J, Aziz A, Chen E, Saeb-Parsy K, Fink J, Sneade R, Hamilton TL, Pask DC, Silber Y, Zhao X, Ghevaert C, Liu P, Green AR. (2014). JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood. 123:3139-3151 

Godfrey AL, Chen E, Pagano F, Silber Y, Campbell PJ, Green AR. (2013). Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica. 98:718-721 

Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, McMullin MF, Boiron J-M, Döhner K, Vannucchi AM, Besses C, Campbell PJ, Green AR. (2012). JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 120:2704-2707 

Chen E, Staudt LM, Green AR. (2012). Janus kinase deregulation in leukemia and lymphoma. Immunity. 36:529-541 

Li J, Kent DG, Chen E, Green AR. (2011). Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 4:311-317 

Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, Ingle CE, Dermitzakis ET, Campbell PJ, Green AR. (2010). Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.. Cancer Cell. 18:524-535 

Chen E, Huang X, Zheng Y, Li Y-J, Chesney A, Ben-David Y, Yang E, Hough MR.(2010) Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1. Mol Cancer. 9:246 

Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, Chen E, Forrai A, Scott LM, Ferreira R, Campbell PJ, Watson SP, Liu P, Erber WN, Huntly BJP, Ottersbach K, Green AR. (2010). JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 116:1528-1538 

Beer PA, Delhommeau F, LeCouédic J-P, Dawson MA, Chen E, Bareford D, Kušec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR. (2010). Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm. Blood. 115:2891-2900 

Wood AD, Chen E, Donaldson IJ, Hattangadi S, Burke KA, Dawson MA, Miranda-Saavedra D, Lodish HF, Green AR, Göttgens B. (2009). ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood. 114:1820-1830 

Chen E, Kwon YT, Lim MS, Dubé ID, Hough MR. (2006). Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice.. Oncogene. 25:5752-5763 

Chen E, Lim MS, Rosic-Kablar S, Liu J, Jolicoeur P, Dubé ID, Hough MR. (2006). Dysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic mice.. Oncogene. 25:2575-2587

Publications

For details of all my research outputs, visit my WestminsterResearch profile.